Abstract Body

Prevention of HIV and unintended pregnancies are public health priorities. We assessed the pharmacokinetics of ?-polycaprolactone implants containing the antiretroviral islatravir (ISL) and the contraceptive etonogestrel (ENG) in macaques.

ISL implants (100µm wall thickness) were administered subcutaneously in the right arm with a trocar. Group-1 (n=3) received a low-dose (LD) and group-2 (n=3) received a mid-dose (MD) ISL implant with an in vitro release-rate (IRR) of 42 and 75 µg/day, respectively. After 4 weeks, group-1 received a second ISL implant with an IRR of 75 µg/day in the left arm to assess a high-dose (HD) of ISL with a cumulative IRR of 117 µg/day. Group-2 received an ENG implant (300µm wall thickness) with an IRR of 40 µg/day in the left arm to assess co-release of ISL and ENG. Blood collections and visual exams were done weekly, and mucosal biopsies were collected biweekly for 14 weeks. ISL, ENG, and progesterone (P4) were measured in plasma and ISL triphosphate (ISL-TP) was measured in PBMCs and tissues. Implant site reactions were scored with a modified Draize scale (0-4) and skin biopsies collected near the implant were H&E stained. PK data from broken implants was excluded from analysis.

Plasma ISL levels were 0.38, 0.60, and 0.88 ng/ml for the LD, MD±ENG, and HD groups, respectively. ISL-TP in PBMCs were sustained for >3 months [LD=24.8, MD±ENG =41.8, HD=75.8 fmol/10^6 cells], but only the HD group achieved levels above the PrEP benchmark (50 fmol/10^6 cells). ISL-TP was detected in vaginal tissue [median: LD=12.2, MD±ENG=14.6, HD=31.3] and rectal tissue [median: LD=18.5, MD±ENG=20.8, HD=30.2 fmol/mg tissue]. P4 production was suppressed by week 2 and plasma ENG peaked at week 3 [875 pg/ml]. No local reactions were observed at implant sites with intact ISL (n=7/9) and ENG (n=3/3) implants. H&E-stained skin biopsies were pathologically unremarkable. Two MD ISL implants broke on day 49 and 56 post-implantation, but only mild redness and edema were observed [median Draize score = 1 (range 0.5-2)].

Implants yielded stable plasma ISL and ISL-TP in PBMCs for >3 months with minimal implant-site reactions when intact. Based on the initial ISL load and estimated IRR, the sustained release of ISL is projected for >2 years. Plasma ENG levels were stable and sufficient to fully suppress progesterone. Evaluation of optimized implants with increased wall thickness is underway for improved durability and vaginal efficacy in a SHIV challenge model.